BCL2A1 and acute myeloid leukemia: The data presented in Figure 2 indicate that treatment with 20(S)-PPD resulted in a reduction of MCL-1 and Bcl-XL levels, while the expression of Bcl-2, Bfl-1, Bax, and Bak remained unaffected across all three tested AML cell lines.